Cortech forges ahead against sepsis

Cortech Inc., deciding that the downside exposure has about taken its toll, will expand its new Phase II trial of Bradycor in sepsis to decide conclusively whether the bradykinin antagonist will work against the condition.

CRTQ, in an update on its clinical programs for Bradycor, said analysis of its completed Phase II trial in SIRS/sepsis led to the decision to expand its ongoing Phase II trial from 100 patients to 250 patients. The new trial, started in May, uses a seven-day infusion versus three days in the earlier study. CRTQ anticipates completing enrollment in the first quarter of 1995 with data announced about mid-year...